ArticleFrontiers in neurology2025
Visual prognosis in idiopathic intracranial hypertension: observations from a retrospective cohort in Germany.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MRI features in atypical idiopathic intracranial hypertension.European radiology · 2026Article
- When headache meets visual disturbance: An evidence-based review of common and critical entities.Science progressReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Idiopathic intracranial hypertension (IIH) is a rare disorder of raised intracranial pressure that can cause visual loss. While risk factors for visual outcome have been explored in international cohorts, no data are available from Germany. This study is the first to evaluate clinical characteristics and predictors of visual deterioration in a large German cohort of IIH patients. Methods: We retrospectively analyzed patients diagnosed with IIH between 2004 and 2020 at a tertiary neurological center. Clinical features, ophthalmologic findings, and treatment strategies were recorded. Visual outcomes were assessed at minimum follow-up of 6 months after IIH diagnosis. Poor visual outcome was defined by worsening of visual function or persistent visual impairment. Regression analysis was utilized to evaluate potential risk-factors of poor visual outcome. Results: The cohort included 191 consecutive IIH patients; follow-up ophthalmologic data were available in 90. Poor visual outcome occurred in 30%. Multivariable regression showed male sex (OR 8.7, Conclusion: Our findings confirm papilledema severity and male sex as prognostic factors identified in prior studies and extend them to a German real-world setting. This strengthens the external validity of existing evidence and underscores the importance of early recognition of high-risk patients to prevent irreversible visual loss.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.